In a report released on April 5, Roanna Ruiz from SVB Securities reiterated a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $13.56.
Ruiz covers the Healthcare sector, focusing on stocks such as Lantheus, Vir Biotechnology, and Pardes Biosciences. According to TipRanks, Ruiz has an average return of -21.1% and a 37.14% success rate on recommended stocks.
NewAmsterdam Pharma Company has an analyst consensus of Moderate Buy, with a price target consensus of $21.00, implying a 54.87% upside from current levels. In a report released on April 3, Credit Suisse also maintained a Buy rating on the stock with a $22.00 price target.
See the top stocks recommended by analysts >>
NAMS market cap is currently $1.1B and has a P/E ratio of -65.71.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Frazier Lifesciences Acquisition Corp is a blank check company.
Read More on NAMS:
- NewAmsterdam appoints Janneke van der Kamp to board of directors
- NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
- NewAmsterdam expects cash to fund operations through 2026
- NewAmsterdam reports 2022 EPS (EUR 0.96) vs. (EUR 1.19) last year
- NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
